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Abstract
Bipolar Disorder (BD), in the depressive phase is among the most common
mental disorder diagnosed in patient’s I treated based on the insight gained after
completing a 10-day reflective practice log at Emergence Health Network, outpatient
services. In my clinical practice, I noticed that when patients with bipolar depression
were on certain antipsychotics, i.e., Aripiprazole, their bipolar disorder, depressive
phase symptoms were not improving. Bipolar depression is a debilitating mental
disorder and if effective treatment is not implemented, the disease can provoke a
suicide death. After an intensive literature review, I found the following guidelines for the
effective treatment of bipolar depression The application of the Canadian Network for
Mood and Anxiety (CANMAT) and the International Society for Bipolar Disorder (ISBD)
2018 guidelines in treating bipolar depression improved and alleviated bipolar
depression symptoms within two weeks. Ten patients were included in this quality
improvement of the Doctor of Nursing Practice (DNP) Project nine reported symptom
improvements and confirmed that the treatment improved their quality of life.
Keywords: Bipolar Disorder, Bipolar Depression, Aripiprazole, CANMAT
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Introduction
Bipolar disorder (BD) is a highly debilitating psychiatric mental disorder that affects 1 out
25 individuals (Miklowitz & Johnson, 2008). BD has its onset in adolescence age and
individuals who suffer from this disorder have mood swings ranging from very high
highs, meaning mania, and very low lows meaning depression (Miklowitz & Johnson,
2008). Bipolar depression has major challenges because it can lead to instability of the
patient’s mental health and other critical medical conditions. Patients with BD face a
high risk of committing suicide. If untreated, the risk factors are 20 times greater than
other major psychiatric conditions (Baldessarini, Vázquez, & Tondo, 2020). Increased
depression is the most prevalent phase for somebody who suffers from BD
(Baldessarini, Vázquez, & Tondo, 2020). Clinical challenges that make these symptoms
difficult to treat include fear of reporting, reluctance to seek help, and patients taking
more medications to manage their BD (Baldessarini, Vázquez, & Tondo, 2020). BD can
lead to loss of job, make patients lag in their academic achievements, and be
unsuccessful in their employment owing to constant absence from work (Baldessarini,
Vázquez, & Tondo, 2020). BD can lead to a high risk of myocardial infarction, strokes,
obesity, increased smoking, a decrease in patients’ longevity If not treated quickly
(Baldessarini, Vázquez, & Tondo, 2020). Evidence demonstrates that the use of
antipsychotics and/or the use of anticonvulsants, short-term or long-term treatments of
BD can assist in obtaining stability and mental well-being (Baldessarini, Vázquez, &
Tondo, 2020).
A 10-day reflective practice log on my place of work at Emergence Health
Network revealed that it took over 2 weeks of outpatient services to maintain proper
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documentation of patients. The log included a plan of care, diagnosis, assessments,
age, and sex of the patient. After analyzing the complete reflective practice log, I gained
insight into all phases of patients’ mental disorders, which was the most prevalent
disease diagnosed. During the care of patients with BD, I explored the quality of their
improvement during the depressive phase since their symptoms failed to improve while
on Aripiprazole.
Previous studies were reviewed to explore a quality improvement associated
with the treatment of bipolar depression. I preferred the Canadian Network for Mood
and Anxiety Treatments (CANMAT) to treat patients BD depressive phase as it
collaborated with the International Society for Bipolar Disorder (ISBD) 2018 guidelines.
Moreover, CANMAT/ISBD 2018 guidelines is preferable because its evidence-based
information is the most recent for treating bipolar depression as its step-by-step
guidelines are easy to follow. The treatment procedures of BD follow evidence-based
recommendations. The CANMAT/ISBD 2018 guidelines used years of research and
available first, second, and third evidence from randomized control trials to suggest
guidelines for treatment (Yatham, et al., 2018). The CANMAT guidelines were available
in 2005 and updated in 2013. The CANMAT's latest update was in 2018, in
collaboration with ISBD, which continue to use the highest level of research for random
control trials. The CANMAT/ISBD 2018 guidelines assist in managing the bipolar
depression phase, bipolar mania phase, and maintenance of the BD. The
CANMAT/ISBD 2018 guidelines represent important advances in the psychiatric care of
the mental disorder, which includes psychological and pharmacological treatments as
they have been making significant updates since its first publication in 2005 (Yatham, et
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al., 2018). The guidelines are comprehensive and easy to follow as their
recommendations are based on clinical experience and evidence-based practice for a
line of treatment. Moreover, the guidelines are safe for patients because it is based on
clinical outcome research (Yatham, et al., 2018). The CANMAT/ISBD 2018 guidelines
describe bipolar depression, according to the DSM-5 diagnostic criteria such as status
of symptom, change in appetite, sleep, low mood, fatigue, lack of interest, and decrease
concentration (Yatham, et al., 2018). The guidelines assess the severity of the
symptoms and the ability to adhere to treatment (Yatham, et al., 2018). Depending on
the type of BD the patient may be suffering from, the CANMAT/ISBD 2018 guidelines
offer the best treatment to manage and improve symptoms. Table 1 presents type 1 and
2 depressive phases for the treatment of BD. Before considering medication, the
guideline recommends assessing any previous medication taken and either maximizing
the current medication, considering adjunctive medication with current medication, or
switching to another medication recommended according to the BD phases. The
strategy will assist in alleviating symptoms and enhancing bipolar disorder stability
(Yatham, et al., 2018). Electroconvulsive therapy (ECT) is recommended as a second
line of treatment for patients requiring rapid response treatment, especially patients with
severe bipolar depression and symptoms of death wishes (Yatham, et al., 2018). The
clinical evidence from the CANMAT/ISBD shows that rapid treatment relief, Quetiapine
relief, and Lurasidone (Latuda) may improve symptoms in approximately one week as
this is the first-line monotherapy or adjunctive treatment (Yatham, et al., 2018). In my
reflective practice log, the numbers of female patients treated for bipolar mental health
disorder are higher than male patients. The CANMAT/ISBD 2018 guidelines offer
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specific suggestions for treating women during their reproductive cycles (Yatham, et al.,
2018).

Table 1 (Yatham, et al., 2018)

First Line of Treatment

Second Line of
Treatment

Bipolar Disorder Type 1
Depressive State
 Quetiapine
Monotherapy
 Lurasidone+Lithium or
Divalproex
 Lithium Monotherapy
 Lamotrigine
Monotherapy
 Lurasidone
monotherapy
 lamotrigine adjunctive







Third Line of Treatment






Bipolar Disorder Type 2
Depressive State
 Quetiapine

Divalproex
monotherapy
SSRI/Bupropion
adjunctive
Cariprazine
monotherapy
Olanzepine+Fluoxetine
ECT (Electroconvulsive
Therapy)



Aripiprazole adjunctive
Armodafinil adjunctive
Carbamazepine
monotherapy
light therapy














Lithium
monotherapy
Lamotrigine
monotherapy
Bupropion
Adjunctive
ECT
Sertraline
Venlafaxine
Bupropion
adjunctive
Divalproex
Fluoxetine
Ziprasidone
TMS (Transcranial
Magnetic
Stimulation) therapy
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The latest collaboration between the CANMAT and the ISBD goal is to publish
efficacious evidence and a range of interventions in improving BD all phases for
symptom relief.
The change model from Kurt Lewin provided insight in implementing the Doctor
of Nursing Practice (DNP) Project. The change model is implemented in three steps: the
unfreezing, moving, and refreezing stages approach used to manage changes (Burnes,
2020). This theoretical framework model is straightforward for processing change,
during the unfreezing change. The theoretical framework also allows the flexibility
necessary for changes since it helps learners to gain knowledge about the upcoming
changes and equips them in identifying problems associated with changes (Burnes,
2020). During the moving stage, changes arising from the intended purpose and forces
in change are greater than the individual who resists change (Burnes, 2020). The final
stage, the freezing process, reinforcing the change, stabilizing the change is
implemented to find equilibrium and decrease the risk of regression (Burnes, 2020). By
reducing the individuals opposing changes and reinforcing the desire to achieve a better
outcome, one can achieve change for more positive outcomes. Using the
CANMAT/ISBD 2018 guidelines for treating BD, Lewin’s model of change implements
the guidelines for quality improvement. Once the steps have been completed, the
process will be re-evaluated, and changes will be done to incorporate the quality
improvement Plan, Do, Study, Act (PDSA) model. This model will facilitate the
guidelines and their effectiveness (AHRQ, 2020). The Plan stage identifies the patients
who qualify for the DNP Program; the Do stage is used to identify the best approach in
change or augmentation of medication; the Study stage evaluates any adverse side
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effects. Improvement in the patient’s symptoms and finally Act stage determined the
successful guidelines and standardized implementation for improving symptoms of
bipolar depression.
Technique in measuring the effectiveness of the treatment is by using the
subjective and objective data from the patient’s history and using the numeric rating
scale to measure pain. The rating scale for pain is modified to serve my purpose in
rating the depressive state of the patient before and after the medication change. The
scale of 0 represents no depressive symptoms and 10 represents highest the bipolar
depressive state. The patient rates their bipolar depressive mood from 0-10. The
numeric rating scale has been validated as it correlates with the patient’s pain
symptoms (Lazariduo, et al., 2018) and will be used to measure bipolar depression. A
Patient-Reported Outcome is an outcome measurement tool that provides direct
reporting of the patient’s response and provides a reliable measurement for symptoms
to improve patient's quality of life (Weldring, Smith, 2013). The 0-10 rating scale is used
to measure patient’s health outcomes and provides insight into the patient’s treatment
(Weldring, Smith, 2013). There will be a numeric count of the patients who meet the
DNP Project criteria.
The guideline’s extensive evidence-based clinical practice and the quality
improvement DNP Project tools are used in treating bipolar depression and improving
the mental health of my patients as well their quality of life. The CANMAT/ISBD 2018
guidelines are tools to improve symptoms and provide patient’s stability globally
(Yatham, et al., 2018). A study published in The International Journal of
Neuropsychopharmacology identified 583 guidelines and treatment algorithms
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(Fountoulakis & Vieta, 2008). Of those 583 articles, 32 randomized control trials studies
demonstrated structural guidelines for the treatment of bipolar depression. A metaanalytical study in this article found that Aripiprazole as a monotherapy strategy offers
excellent treatment using for acute mania phase BD compared to a placebo at 15-30
mg per day. Aripiprazole also provided negative endpoints when compared with placebo
in treating acute bipolar depression (Fountoulakis & Vieta, 2008). In another metaanalysis of random control trial, an article published in the International Journal of
Neuropsychopharmacology recommended Quetiapine or Lurasidone (Latuda) and
cognitive behavioral therapy as the first-line treatment for bipolar depression. However,
the article suggests avoiding using cognitive behavioral therapy monotherapy
(Konstantinos, et al., 2017). The World Journal of Biological Psychiatry also suggested
Lurasidone (Latuda) as more effective compared to Aripiprazole and Ziprasidone in
treating bipolar depression (Ostacher, et al., 2018). Lurasidone (Latuda) compared to
Quetiapine was also effective, it was less sedative and offered similar benefits
(Ostacher, et al., 2018). The Journal of Psychopharmacology suggested using effective
guidelines and the evidence-based clinical experience supported by research ranging
from level I, the highest hierarchy levels, to level IV, for treatment of BD (Goodwin, et
al., 2016). These guidelines offer standards of care based on evidence to improve the
BD symptoms, especially for the DNP Project, Bipolar Depression. However,
Aripiprazole, as a monotherapy treatment, has not been effective compared to a
placebo in treating bipolar depression; but it is the first line of treatment for bipolar
mania (Yatham, et al., 2018). The Current Psychiatry Reports, published in 2021,
revealed that oral Aripiprazole as monotherapy was not effective in improving acute
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bipolar depressive symptoms (Keramatian, et al., 2021). Table 2 presents a PICOT
question format for the quality improvement project. Three PICOT questions were
developed and the one mentioned was my first choice. Patients who met inclusion
criteria are those who currently use Aripiprazole and have bipolar depressive
symptoms. After patient identification, evidence-based literature from the
CANMAT/ISBD 2018 guidelines is used to improve and alleviate bipolar depressive
symptoms. Before proceeding with my DNP project for Quality Improvement (QI), a QI
project proposal was developed, and an approval letter was received from the
Institutional Review Board (IRB) of The University of Texas at El Paso to proceed with
my worksite at Emergence Health Network outpatient clinic. A code of conduct is
assumed to be the utmost standard of care in treating my patients and in providing
quality improvement for the DNP Project. I am a certified PMHNP (Psychiatric Mental
Health Nurse Practitioner), which is within my scope of practice and allows me to
practice, assess, diagnose, treat, and evaluate patients. The privacy of the patients will
be maintained by following the standards of the HIPPA (Health Insurance Portability and
Accountability) act.
Table 2 PICOT

o Population: Patients 21 to 65 years old with bipolar disorder with
continued bipolar depression
o Interventions: Use CANMAT/ISB 2018 Bipolar Depression Guidelines
o Current practice: Using Oral Aripiprazole 10 mg QHS
o Outcome: Desire outcome it to alleviate bipolar depression symptoms
o Time: 4 weeks
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Methods
The Emergence Health Network was the DNP project location. The
CANMAT/ISBD 2018 guidelines were used to treat the outpatient population with bipolar
depression. The participants are the patient and me. My supervising MD was aware of
the project and granted full autonomy. He made himself available for consultation. The
project barrier was the possibility of the client not returning within the DNP Project
timeframe. The DNP Project treatment was individualized and implemented for each
patient. The quality improvement was evaluated after the implementation and outcome
of the DNP Project. The DNP Project started on January 18, 2022 and aimed at treating
bipolar depression using the CANMAT/ISBD 2018 guidelines implementation. Inclusion
criteria were females and males subjects aged 18-65 years old; patients who took
Aripiprazole and patients diagnosed with bipolar depression. Once the patient was
identified and met the criteria for the DNP Project, we started the CANMAT/ISBD 2018
guidelines, proceeded with the recommendations, and started the appropriate
treatment. In the first and second weeks, the patients were identified for the DNP
Project. Moreover, the patients were assessed, and their depressive symptoms were
rated using the rating scale of 0/10. Moreover, I took subjective and objective data from
the patients. The next stage was to provide information for treating patient’s bipolar
depression. With the patient’s permission, I will change their medication if possible, or
maximized current medication or add other medication by following the CANMAT/ISBD
2018 guidelines. I will assess the patient’s current Aripiprazole and if they had any other
antipsychotics in the past. If the patient did not take another antipsychotic in the past
from the suggested guidelines, I will offer first-line treatment to improve bipolar
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depression symptoms. If the patient responded to antipsychotic drugs in the past and as
one of the first-line treatments, we offered first-line adjunctive medication or second-line
treatment medication if applicable. The same procedure will be implemented for the
patient who suffered from BD type 2 depressive phase. While on Aripiprazole, I will start
other antipsychotics or continued Aripiprazole based on the guideline’s suggestion to
the patient and the patient’s agreement to proceed. Aripiprazole half-life is 75 hours and
is eliminated in 2 weeks after stopping the drug (Keks, Schwartz, Hope, 2019). A cross
titration will be conducted by reducing Aripiprazole by 50% and will be stopped after 14
days (Keks, Schwartz, Hope, 2019). I will switch to the recommended medication to be
started on Day 1 (Keks, Schwartz, Hope, 2019). I will start the new antipsychotic
medication following the recommended dose and increased the medication accordingly.
After following the pharmacological CANMAT/ISBD 2018 guidelines, I will follow-up with
the patient for two weeks for evaluation purposes. After medication change, the patient
will be informed to call the clinic if they experienced any adverse side effects to make
any necessary changes before the next follow-up appointments. During the follow-up, I
will evaluate the patient’s depressive state using the rating scale. In addition, I will
assess if the patient tolerates the treatment. Moreover, I will follow the CANMAT/ISBD
2018 guidelines to treat side effects. Importantly, I will take the patient’s consideration
and respected their right in agreeing or declining change by following the ethical
consideration and supporting the patient’s decision. However, I do not anticipate any
conflict of interest while conducting the quality improvement. Table 3 provides a
flowchart for the treatment interventions of the DNP Project. Bipolar depression
symptoms should improve after following the implemented guidelines.
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Table 3 Flowchart

Identified The
Patient

Assess The Type Of
BD

Obtain Patient's
permission for
Medication
Adjustment

Use Guidelines

Follow Up In 2
Weeks

Evaluate
Medications
Outcome

Continue to Make
Adjusments
Accordinly

Results
The DNP Project started on January 18, 2022 and ended on February 17, 2022.
A total of 160 hours were used for the project and 10 patients who met the inclusion
criteria for the DNP Program were identified and treated. The age range of the patients
was 22-49 years old. 40% males and 60% females were applicable for DNP project.
Three patients had a diagnosis of bipolar two disorder and seven patients had a
diagnosis of bipolar one disorder. Table 4a, 4b, and 4c provide patient demographics
information. In the first two weeks, 10 patients were identified for the DNP Project. Eight
out of ten patients were weaned off Aripiprazole. Some of the patients have taken
Aripiprazole for several months or years and experienced more phases of depressive
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bipolar disorder compared to manic. Wean off process took 14 days without any
adverse effects.
Table 4a Demographics

AGES

18-29

Column1

30-39
18-29
5

40-49
30-39
4

40-49
1
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Table 4b Demographic

GENDER
Males

Females

40%

60%

Table 4c Demographics

Ethnicity/Race

40%
Hispanic
White
60%

1 out of 10 patients refused to switch Aripiprazole but was opened to add an
adjunctive medication. Another patient out of 10 refused to switch, adjusted current
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medication, to add adjunctive medication, and his right was respected. This patient was
included in the DNP Project as it met requirements and the patient was followed up for
two weeks to see if symptoms continued or if allowed, to opt for a medication change in
the follow-up appointment. The patient did not want his medication to be adjusted during
initial intervention. Those 10 patients rated their depressive phase 8-10/10 on day one.
Four patients were placed on Lurasidone (Latuda); two patients switched to Quetiapine;
two patients switched to Cariprazine (Vraylar), and one of the patients who refused to
switch added Lamotrigine as an adjunctive. The one patient who refused to change
medication, was continued with current dosage as requested. Two of the patients who
changed to Lurasidone (Latuda) complained of nausea for 1-2 days. Then, side effects
improved. I did not encounter any conflict of interest as foreseen. After the two-week
follow-up, assessment and evaluation were done; a rating scale was performed; nine
patients reported a 2–5 point decrease in their depressive symptoms and one patient
did not experience any change in their depressive symptoms. For those patients
reporting 2 points decreased, I considered increasing dose to improve symptoms, of
which the patient agreed. Their medication was Lurasidone (Latuda) 20 mg, which was
increased to 40 mg per day and to be taken with food. Two other patients who took
Lurasidone (Latuda) reported feeling stable at starting dose of 20 mg and continued
with the current dosage. One patient who took Quetiapine at 100 mg every night
reported feeling stable and had 5 points decrease in their rating scale. Other patients
reported 2 points rating scale decrease, recommended medication adjustment and
agreed to take 200 mg of Quetiapine at night. The patient who took Cariprazine
(Vraylar) had 2-3 points decrease in their rating scale from their starting doses of 1.5 mg
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and continued the dosage as per their request due to reported feeling stable. One
patient who opt adjunctive, took Lamotrigine with Aripiprazole, that medication was
titrated slow, started at 25 mg in week one and increased to 50 mg in week two due to
its risk of adverse reaction of rash, which could lead to Steven-Johnson Syndrome. This
treatment was supported by the guidelines (Yatham, et al. 2018). This patient had a 2point decrease in their initial rating scale, and medication was increased to the target
goal at 100 mg based on the patient’s agreement to improve symptoms. The rating
scale of the patient, who initially refused any change in depressive symptoms, did not
change. During day one and follow-up day, the rating scale was 9/10; the patient agreed
to increase the dosage of Aripiprazole 15 mg at night. However, he did not want to
change his medication. I suggested considering psychotherapy, which was included in
the CANMAT/ISBD 2018 guidelines. The patient responded that he would consider this
in the future. His medication was adjusted with a two-week follow-up. Those patients
who agreed with the medication change were received in two weeks to continue an
evaluation of symptoms. Table 5a presents the rating scale of the 10 patients. Table 5b
presents their outcomes. The application of the CANMAT/ISBD 2018 guidelines was
effective in treating bipolar depression. The guidelines provided step-by-step in treating
bipolar depression, which was based on the years of evidence-based clinical validity.
The average decrease of the rating scale point was 2.6. The patient reported
improvement in symptoms based on medication change. The CANMAT/ISBD 2018
guidelines on medication were well tolerated during their research and were confirmed
by my DNP Project as two out of ten patients reported nausea. However, during the last
one to two days, no adverse effects were reported. Certain insurances did not approve
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brand-name medication currently only sold version of Lurasidone (Latuda) and
Cariprazine (Vraylar). Some insurance companies approved Cariprazine (Vraylar) and
not Lurasidone (Latuda) and vice versa.
Discussion
The CANAMT/ISBD 2018 guidelines were found to be useful in treating bipolar
depression as they did alleviate bipolar depressive symptoms. The bipolar depression
symptoms improved in the DNP project timeframe. These CANMAT/ISBD 2018
guidelines can be used for the treatment of the entire bipolar disorder spectrum, not
only for bipolar depression phases because these guidelines provide an effective
evidence-based clinical experience in the entire BD spectrum (Yatham, et al., 2018).
The CANMAT/ISBD 2018 guidelines allowed patients to feel stable and improved their
daily activities. More options of antipsychotics are available in treating bipolar one
disorder compared to bipolar two disorder as the first line of treatment guidelines stated.
Bipolar two has been understudied owing to a long-standing of bipolar one (Yatham, et
al., 2018). Quetiapine is the only antipsychotic that FDA approves as the classification
to treat bipolar two depressive phase (Yatham, et al. 2018). The CANMAT/ISBD
guidelines will need an update due to as of December 2021, Lumateperone (Caplyta)
was included as another FDA-approved medication for the treatment of bipolar one and
two depressive phases (Sanchez, 2021).
Certain Brand name medications like Lurasidone (Latuda) or Cariprazine
(Vraylar) were not approved by insurance. In this project, a patient confirmed that his
insurance did not provide Lurasidone (Latuda) coverage but covered Cariprazine
(Vraylar), which was not a first-line or not second-line treatment but a third-line
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treatment. However, the medication alleviated bipolar depressive symptoms. Some
insurances provided brand name medication if the patient failed other generic
antipsychotics. Information of previously failed generic antipsychotic medication is
provided to insurance companies and sending a prior authorization may be needed. The
CANMAT/ISBS 2018 guidelines provide brand only medication and generic
antipsychotics which are in most private or federal insurance medication formularies but
depends upon the insurance approval of such medication. During this quality
improvement, no limitations were encountered because patients who met the DNP
project criteria were included. The DNP Project CANMAT/ISBD 2018 guidelines were
effective for bipolar depression treatment because they eliminated guessing when it
came to treating such depressive phase in the bipolar spectrum. I will incorporate these
guidelines in my practice to improve bipolar disorder symptoms, reach patients’ stability,
and improve patients their quality of life.
Other Information
I would like to thank my lovely family for their understanding and assistance
granted in completing this DNP project. I also thank the Paso Del Norte Health
Foundation for providing the program award to complete the Scholarly DNP Project. I
would also like to thank Cohort X for all the support they offered during the two-year
program at The University of Texas at El Paso. I like to give thank you to Dr. Hector,
Morales for his guidance and motivation in completing the DNP Program. The revised
standards of quality improvement reporting excellence SQUIRE 2 format were used for
this manuscript (SQUIRE, 2020).
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Table 5a Patient Outcome

Patients
1. Aripiprazole,
added
Lamotrigine
2. Aripiprazole
switch to
Lurasidone
(Latuda)
3. Aripiprazole &
Lamotrigine,
switch
antipsychotic to
Quetiapine
4. Aripiprazole
switch to
Cariprazine
(Vraylar)
5. Aripiprazole
switch to
Cariprazine
(Vraylar)
(Lurasidone was
not approve by
insurance and
took Quetiapine in
the past)
6. Aripiprazole
switch to
Lurasidone (Took
Quetiapine in the
past and did not
tolerated side
effects)
7. Aripiprazole
switch to
Quetiapine
8. Aripiprazole
switch to
Lurasidone (Took
Quetiapine in the
past and did not
tolerated side
effects)
9. Aripiprazole
switch to
Lurasidone
10. Aripiprazole, no
switch, no
adjunctive
medication

Day 1 Rating Scale

Follow up Rating
Scale

Bipolar Disorder
Type

10/10

8/10 (-2)

Bipolar Disorder
Type 1

9/10

6/10 (-3)

Bipolar Disorder
Type 1

10/10

5/10 (-5)

Bipolar Disorder
Type 2

9/10

7/10 (-2)

Bipolar Disorder
Type 1

8/10

6/10 (-2)

Bipolar Disorder
Type 1

9/10

6/10 (-3)

Bipolar Disorder
Type 1

9/10

6/10 (-3)

Bipolar Disorder
Type 2

8/10

5/10 (-3)

Bipolar Disorder
Type 1

9/10

6/10 (-3)

Bipolar Disorder
Type 1

9/10

9/10 (0)

Bipolar Disorder
Type 1
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Figure 5b Patient Outcome
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